Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.

Tintelnot J, Stein A.

World J Gastroenterol. 2019 Aug 7;25(29):3920-3928. doi: 10.3748/wjg.v25.i29.3920. Review.

2.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.

PMID:
30824613
3.

Arc/Arg3.1 defines dendritic cells and Langerhans cells with superior migratory ability independent of phenotype and ontogeny in mice.

Tintelnot J, Ufer F, Engler JB, Winkler H, Lücke K, Mittrücker HW, Friese MA.

Eur J Immunol. 2019 May;49(5):724-736. doi: 10.1002/eji.201847797. Epub 2019 Mar 6.

PMID:
30786014
4.

Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation.

Ufer F, Vargas P, Engler JB, Tintelnot J, Schattling B, Winkler H, Bauer S, Kursawe N, Willing A, Keminer O, Ohana O, Salinas-Riester G, Pless O, Kuhl D, Friese MA.

Sci Immunol. 2016 Sep 23;1(3):eaaf8665. doi: 10.1126/sciimmunol.aaf8665.

PMID:
28783680

Supplemental Content

Loading ...
Support Center